BIOLASE REPORTS THIRD QUARTER FINANCIAL RESULTS; COMPANY BENEFITTING FROM STRATEGIC ACTIONS TAKEN TO STREAMLINE OPERATIONS AND GAIN GREATER OPERATIONAL EFFICIENCIES
- Gross margin improved to 34% from 20% year over year
- Operating expenses decreased by 26% year over year
- Company expects full year 2023 revenue to be 1 to 3% higher than full year 2022 revenue
- 9% decrease in net revenue for the third quarter of 2023
- 17% decrease in U.S. laser revenue
- Total revenue was
$10.9 million - Total consumable sales were
$2.9 million 10% year-over-year increase as utilization of installed laser systems continues to increase - Gross margin was
34% , a 1,400-basis expansion compared to the year-ago level due to the specific actions taken by the Company to drive toward profitability - Continued operating improvements and efficiencies reduced operating loss by
52% year over year compared to the year-ago quarter
"We are continuing to experience heightened interest in our industry-leading dental lasers; however, the uncertainty caused by the macroeconomic environment is extending our sales cycle," commented John Beaver, President, and Chief Executive Officer of BIOLASE. "We believe there are several factors contributing to the longer decision-making process, including higher interest rates. However, it's critical that we maintain our revenue-generating activities to drive greater awareness and interest in our award-winning lasers so that when we return to a more normalized economic climate, we are ready to capitalize on the significant market opportunity we have in front of us. We remain encouraged that new customer acquisition efforts remain strong and the utilization by our installed base continues to grow, as evidenced by the
Net revenue for the quarter ended September 30, 2023 was
Gross margin for the quarter ended September 30, 2023 was
The Company had cash and cash equivalents of approximately
The Non-GAAP Financial Measures at the end of this news release provide the details of the Company's non-GAAP disclosures and the reconciliation of GAAP net loss and net loss per share to the Company's adjusted EBITDA and adjusted EBITDA per share.
Net loss attributable to common stockholders for the quarter ended September 30, 2023 was
The Company currently expects full year 2023 revenue to be 1 to
BIOLASE, Inc. will host a conference call today at 4:30 p.m. Eastern Time to discuss its operating results for the third quarter ended September 30, 2023, and to answer questions. To access the live call, dial 1-866-682-6100 (
A live and archived webcast of the conference call will be accessible on the BIOLASE Investor Relations page. In addition, a phone replay will be available approximately two hours following the end of the call, and it will remain available for one week. To access the call replay, dial 1-877-481-4010 or +1 919-882-2331 (International) and enter replay passcode: 49456.
BIOLASE is a medical device company that develops, manufactures, markets, and sells laser systems in dentistry and medicine. BIOLASE's products advance the practice of dentistry and medicine for patients and healthcare professionals. As of December 31, 2022, BIOLASE's proprietary laser products incorporate approximately 259 active patents and 24 patent-pending technologies designed to provide biologically and clinically superior performance with less pain and faster recovery times. BIOLASE's innovative products provide cutting-edge technology at competitive prices to deliver superior results for dentists and patients. BIOLASE's principal products are dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications. From 1998 through December 31, 2022, BIOLASE has sold over 45,500 laser systems in over 80 countries around the world. Laser products under development address BIOLASE's core dental market and other adjacent medical and consumer applications.
BIOLASE®, Waterlase® and Waterlase iPlus® are registered trademarks of BIOLASE, Inc.
This press release contains forward-looking statements, as that term is defined in the Private Securities Litigation Reform Act of 1995, that involve significant risks and uncertainties, including statements, regarding BIOLASE's expected revenue and revenue growth. Forward-looking statements can be identified through the use of words such as "may," "might," "will," "intend," "should," "could," "can," "would," "continue," "expect," "believe," "anticipate," "estimate," "predict," "outlook," "potential," "plan," "seek," and similar expressions and variations or the negatives of these terms or other comparable terminology. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect BIOLASE's current expectations and speak only as of the date of this release. Actual results may differ materially from BIOLASE's current expectations depending upon a number of factors. These factors include, among others, adverse changes in general economic and market conditions, competitive factors including, but not limited to, pricing pressures and new product introductions, uncertainty of customer acceptance of new product offerings and market changes, risks associated with managing the growth of the business, substantial doubt regarding BIOLASE's ability to continue as a going concern, inability to raise additional capital on terms acceptable to BIOLASE and those other risks and uncertainties that are described in the "Risk Factors" section of BIOLASE's most recent annual report on Form 10-K and quarterly report on Form 10-Q filed with the Securities and Exchange Commission. Except as required by law, BIOLASE does not undertake any responsibility to revise or update any forward-looking statements.
For further information, please contact:
EVC Group LLC
Michael Polyviou / Todd Kehrli
(732) 933-2754
mpolyviou@evcgroup.com / tkehrli@evcgroup.com
BIOLASE, INC. | ||||||||||||||||
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS | ||||||||||||||||
(Unaudited, in thousands, except per share data) | ||||||||||||||||
Three Months Ended | Nine Months Ended | |||||||||||||||
September 30, | September 30, | |||||||||||||||
2023 | 2022 | 2023 | 2022 | |||||||||||||
Net revenue | $ | 10,921 | $ | 12,010 | $ | 35,674 | $ | 34,411 | ||||||||
Cost of revenue | 7,175 | 9,565 | 22,474 | 22,096 | ||||||||||||
Gross profit | 3,746 | 2,445 | 13,200 | 12,315 | ||||||||||||
Operating expenses: | ||||||||||||||||
Sales and marketing | 3,402 | 5,008 | 14,214 | 15,224 | ||||||||||||
General and administrative | 2,679 | 3,109 | 7,495 | 8,825 | ||||||||||||
Engineering and development | 1,362 | 1,979 | 4,352 | 5,177 | ||||||||||||
Total operating expenses | 7,443 | 10,096 | 26,061 | 29,226 | ||||||||||||
Loss from operations | (3,697) | (7,651) | (12,861) | (16,911) | ||||||||||||
Loss on foreign currency transactions | (307) | (329) | (522) | (552) | ||||||||||||
Interest expense, net | (598) | (424) | (1,758) | (1,287) | ||||||||||||
Other income (expenses), net | 28 | — | (119) | — | ||||||||||||
Non-operating loss, net | (877) | (753) | (2,399) | (1,839) | ||||||||||||
Loss before income tax (provision) benefit | (4,574) | (8,404) | (15,260) | (18,750) | ||||||||||||
Income tax (provision) benefit | (15) | 17 | (46) | (23) | ||||||||||||
Net loss | (4,589) | (8,387) | (15,306) | (18,773) | ||||||||||||
Other comprehensive loss items: | ||||||||||||||||
Foreign currency translation adjustments | (105) | (152) | 14 | (415) | ||||||||||||
Comprehensive loss | $ | (4,694) | $ | (8,539) | $ | (15,292) | $ | (19,188) | ||||||||
Net loss | $ | (4,589) | $ | (8,387) | $ | (15,306) | $ | (18,773) | ||||||||
Deemed dividend on convertible preferred stock | — | — | — | (217) | ||||||||||||
Net loss attributable to common stockholders | $ | (4,589) | $ | (8,387) | $ | (15,306) | $ | (18,990) | ||||||||
Net loss per share attributable to common stockholders: | ||||||||||||||||
Basic and Diluted | $ | (3.89) | $ | (110.36) | $ | (22.28) | $ | (287.73) | ||||||||
Shares used in the calculation of net loss per share: | ||||||||||||||||
Basic and Diluted | 1,179 | 76 | 687 | 66 | ||||||||||||
BIOLASE, INC. | ||||||||
CONSOLIDATED BALANCE SHEETS | ||||||||
(Unaudited, in thousands, except per share data) | ||||||||
September 30, | December 31, | |||||||
2023 | 2022 | |||||||
(Unaudited) | (Audited) | |||||||
ASSETS | ||||||||
Current assets: | ||||||||
Cash and cash equivalents | $ | 7,809 | $ | 4,181 | ||||
Accounts receivable, less allowance of | 4,388 | 5,841 | ||||||
Inventory | 13,824 | 15,884 | ||||||
Prepaid expenses and other current assets | 1,761 | 3,053 | ||||||
Total current assets | 27,782 | 28,959 | ||||||
Property, plant, and equipment, net | 6,049 | 4,278 | ||||||
Goodwill | 2,926 | 2,926 | ||||||
Right-of-use assets, leases | 1,718 | 1,768 | ||||||
Other assets | 270 | 255 | ||||||
Total assets | $ | 38,745 | $ | 38,186 | ||||
LIABILITIES, CONVERTIBLE REDEEMABLE PREFERRED STOCK AND | ||||||||
Current liabilities: | ||||||||
Accounts payable | $ | 7,178 | $ | 5,786 | ||||
Accrued liabilities | 7,613 | 9,210 | ||||||
Deferred revenue, current portion | 2,191 | 2,111 | ||||||
Current portion of term loans, net of discount | 2,800 | 700 | ||||||
Total current liabilities | 19,782 | 17,807 | ||||||
Deferred revenue | 236 | 418 | ||||||
Warranty accrual | 463 | 360 | ||||||
Non-current term loans, net of discount | 11,307 | 13,091 | ||||||
Non-current operating lease liability | 995 | 1,259 | ||||||
Other liabilities | 78 | 362 | ||||||
Total liabilities | 32,861 | 33,297 | ||||||
Series H Convertible Preferred stock, par value | 300 | — | ||||||
Series J Convertible Preferred stock, par value | 5,252 | — | ||||||
Total mezzanine equity | 5,552 | — | ||||||
Stockholders' equity: | ||||||||
Common stock, par value | 2 | — | ||||||
Additional paid-in capital | 312,523 | 301,790 | ||||||
Accumulated other comprehensive loss | (719) | (733) | ||||||
Accumulated deficit | (311,474) | (296,168) | ||||||
Total stockholders' equity | 332 | 4,889 | ||||||
Total liabilities, convertible redeemable preferred stock and | $ | 38,745 | $ | 38,186 | ||||
BIOLASE, INC. | ||||||||
CONSOLIDATED STATEMENTS OF CASH FLOWS | ||||||||
(Unaudited, in thousands) | ||||||||
Nine Months Ended | ||||||||
September 30, | ||||||||
2023 | 2022 | |||||||
Cash Flows from Operating Activities: | ||||||||
Net loss | $ | (15,306) | $ | (18,773) | ||||
Adjustments to reconcile net loss to net cash and cash equivalents used in operating activities: | ||||||||
Depreciation | 2,133 | 369 | ||||||
Provision for bad debts | 60 | 56 | ||||||
Provision for inventory excess and obsolescence | — | 245 | ||||||
Inventory write-offs and disposals | — | 1,486 | ||||||
Amortization of debt issuance costs | 320 | 197 | ||||||
Change in fair value of warrants | (104) | — | ||||||
Issuance costs for warrants | 447 | — | ||||||
Stock-based compensation | 1,050 | 1,691 | ||||||
Changes in operating assets and liabilities: | ||||||||
Accounts receivable | 1,393 | (664) | ||||||
Inventory | (720) | (5,229) | ||||||
Prepaid expenses and other current assets | 1,322 | (850) | ||||||
Accounts payable and accrued liabilities | (2,301) | 664 | ||||||
Deferred revenue | (102) | (371) | ||||||
Net cash and cash equivalents used in operating activities | (11,808) | (21,179) | ||||||
Cash Flows from Investing Activities: | ||||||||
Purchases of property, plant, and equipment | (1,126) | (3,256) | ||||||
Net cash and cash equivalents used in investing activities | (1,126) | (3,256) | ||||||
Cash Flows from Financing Activities: | ||||||||
Proceeds from the sale of common stock and pre-funded warrants, net of fees | 8,503 | 5,635 | ||||||
Proceeds from the sale of Convertible Preferred Stock, net of fees | 5,490 | — | ||||||
Proceeds from the sale of warrants, net of fees | 1,743 | — | ||||||
Principal payment on loan | — | (1,000) | ||||||
Proceeds from the exercise of common stock warrants | 114 | — | ||||||
Proceeds from the exercise of preferred share warrants | 699 | — | ||||||
Net cash and cash equivalents provided by financing activities | 16,549 | 4,635 | ||||||
Effect of exchange rate changes | 13 | (415) | ||||||
Increase (decrease) in cash, cash equivalents and restricted cash | 3,628 | (20,215) | ||||||
Cash, cash equivalents and restricted cash, beginning of period | 4,181 | 30,175 | ||||||
Cash and cash equivalents, end of period | $ | 7,809 | $ | 9,960 | ||||
Supplemental cash flow disclosure: | ||||||||
Cash paid for interest | $ | 1,419 | $ | 1,110 | ||||
Cash received for interest | $ | 7 | $ | 23 | ||||
Cash paid for income taxes | $ | 12 | $ | 39 | ||||
Cash paid for operating leases | $ | 230 | $ | 219 | ||||
Non-cash right-of-use assets obtained in exchange for lease obligation | $ | 483 | $ | 562 | ||||
Deemed dividend on preferred stock | $ | — | $ | 217 | ||||
Common stock issued upon exercise of preferred stock | $ | 18,503 | $ | — | ||||
In addition to the financial information prepared in conformity with generally accepted accounting principles in the
Adjusted EBITDA is defined as net loss before interest, taxes, depreciation, stock-based and other non-cash compensation, severance expense, change in allowance for doubtful accounts, increase in inventory reserves, and other (income) expense, net. Management uses adjusted EBITDA in its evaluation of the Company's core results of operations and trends between fiscal periods and believes that these measures are important components of its internal performance measurement process. Therefore, investors should consider non-GAAP financial measures in addition to, and not as a substitute for, or as superior to, measures of financial performance prepared in accordance with GAAP. Further, the non-GAAP financial measures presented by the Company may be different from similarly named non-GAAP financial measures used by other companies.
BIOLASE, INC. | ||||||||||||||||
Reconciliation of GAAP Net Loss to Adjusted EBITDA and | ||||||||||||||||
GAAP Net Loss Per Share to Adjusted EBITDA Per Share | ||||||||||||||||
(Unaudited, in thousands, except per share data) | ||||||||||||||||
Three Months Ended | Nine Months Ended | |||||||||||||||
September 30, | September 30, | |||||||||||||||
2023 | 2022 | 2023 | 2022 | |||||||||||||
GAAP net loss attributable to common stockholders | $ | (4,589) | $ | (8,387) | $ | (15,306) | $ | (18,990) | ||||||||
Deemed dividend on convertible preferred stock | — | — | — | 217 | ||||||||||||
GAAP net loss | $ | (4,589) | $ | (8,387) | $ | (15,306) | $ | (18,773) | ||||||||
Adjustments: | ||||||||||||||||
Interest expense, net | 598 | 424 | 1,758 | 1,287 | ||||||||||||
Income tax (provision) benefit | 15 | (17) | 46 | 23 | ||||||||||||
Depreciation | 560 | 122 | 2,133 | 369 | ||||||||||||
Severance expense | 1 | — | 230 | — | ||||||||||||
Change in allowance for doubtful accounts | 18 | (87) | 60 | 56 | ||||||||||||
Stock-based and other non-cash compensation | 276 | 591 | 1,050 | 1,691 | ||||||||||||
Increase in inventory reserves | — | 1,731 | — | 1,731 | ||||||||||||
Other (income) expense, net | (28) | — | 119 | — | ||||||||||||
Adjusted EBITDA | $ | (3,149) | $ | (5,623) | $ | (9,910) | $ | (13,616) | ||||||||
GAAP net loss attributable to common stockholders | $ | (3.89) | $ | (110.36) | $ | (22.28) | $ | (287.73) | ||||||||
Deemed dividend on convertible preferred stock | — | — | — | 3.29 | ||||||||||||
GAAP net loss per share, basic and diluted | $ | (3.89) | $ | (110.36) | $ | (22.28) | $ | (284.44) | ||||||||
Adjustments: | ||||||||||||||||
Interest expense, net | 0.51 | 5.58 | 2.56 | 19.50 | ||||||||||||
Income tax (provision) benefit | 0.01 | (0.22) | 0.07 | 0.35 | ||||||||||||
Depreciation | 0.47 | 1.61 | 3.10 | 5.59 | ||||||||||||
Severance expense | — | — | 0.33 | — | ||||||||||||
Change in allowance for doubtful accounts | 0.02 | (1.14) | 0.09 | 0.85 | ||||||||||||
Stock-based and other non-cash compensation | 0.23 | 7.78 | 1.53 | 25.62 | ||||||||||||
Increase in inventory reserves | — | 22.76 | — | 26.23 | ||||||||||||
Other (income) expense, net | (0.02) | — | 0.17 | — | ||||||||||||
Adjusted EBITDA per share, basic and diluted | $ | (2.67) | $ | (73.99) | $ | (14.43) | $ | (206.30) | ||||||||
Other (income) expense, net for the three and nine months ended September 30, 2023 relates to issuance costs from the May 2023 public offering that were allocated to the Series H warrants, and issuance costs from the September 2023 public offering that were allocated to the Series J warrants and immediately expensed due to the liability classification of the warrants. These expenses were partially offset by gains recorded on the revaluation of these warrants during the periods.
View original content to download multimedia:https://www.prnewswire.com/news-releases/biolase-reports-third-quarter-financial-results-company-benefitting-from-strategic-actions-taken-to-streamline-operations-and-gain-greater-operational-efficiencies-301983980.html
SOURCE BIOLASE, Inc.
FAQ
What is the net revenue for BIOLASE, Inc. in the third quarter of 2023?
What is the gross margin for BIOLASE, Inc. in the third quarter of 2023?
What are the full year 2023 revenue expectations for BIOLASE, Inc.?
